CLP Holdings' Profit Rose on Better Earnings From Australia, Hong Kong
By Kimberley Kao
CLP Holdings' first-half net profit rose 18%, thanks to improved contributions from unit EnergyAustralia and the Hong Kong operations, offsetting lower power generation from its China business.
Net profit rose to 5.95 billion Hong Kong dollars (US$762.1 million) in the first six months of 2024, from HK$5.06 billion in the year-ago period, the Hong Kong-listed power company said in a filing Monday. Revenue rose 1.8% to HK$44.09 billion.
CLP's operating earnings before fair value movements increased 22% to HK$5.68 billion, thanks to improved contributions from EnergyAustralia's forward energy contracts, which offset lower generation from its two nuclear plants in China due to scheduled maintenance work, the company said.
Growth in demand for electricity was also seen in Hong Kong, driven by the increased pace in Hong Kong's economic recovery, combined with rising temperatures, which pushed up consumption across most sectors, the company said.
CLP declared a second interim dividend of HK$0.63 per share, the same as the first interim dividend and unchanged from a year ago.
Write to Kimberley Kao at kimberley.kao@wsj.com
(END) Dow Jones Newswires
August 05, 2024 00:56 ET (04:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks